Effectiveness and Safety Profile of Fingolimod in Treating Omani Patients with Multiple Sclerosis: A single tertiary centre experience
Sultan Qaboos University Medical Journal · 02.05.2025 · 25 (1) · 225-232
DOI: 10.18295/2075-0528.2829 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sultan Qaboos University Medical Journal, online erschienen am 02.05.2025. Verfasst von Ghaida K H Al-Hashmi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, College of Medicine & Health Sciences, Sultan Qaboos University and Sultan Qaboos University Hospital, University Medical Cit…. Hauptthemen laut MEDLINE: Fingolimod Hydrochloride, Multiple Sclerosis, Immunosuppressive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-ND 4.0).
Abstract (Originalsprache)
Objectives
This study aimed to evaluate the effectiveness and safety of fingolimod in Omani multiple sclerosis (MS) patients. Fingolimod is one of the oral drugs used to treat MS. However, there is limited information on its effectiveness and safety among the Omani population.
Methods
This retrospective real-world study included 65 Omani MS patients who received fingolimod therapy from 2012 to 2021 at a single tertiary centre in Oman. Data were collected between August and November 2021. Various measures were used to evaluate the effectiveness and safety of fingolimod.
Results
Out of 65 MS patients included in the study, 51 (79%) were female. The median duration of fingolimod use was 3.6 ± 2.5 years. The results of the last follow-up visit indicate that the median annualised relapse rate decreased by 84% and relapse-free rate (RFR) increased to 90%, with only a minimal (13%) increase in the expanded disability status. The median number of gadolinium-enhanced lesions in the brain and spine decreased significantly by 88% and 67%, respectively, while the new or enlarged T2 lesions in the brain significantly decreased by 62% (P < 0.050) over the treatment period. The most common side effect was bradycardia (32%). Patient age and age at treatment initiation were significant predictors of RFR (P < 0.050).
Conclusion
This study suggests that the effectiveness and safety profiles of fingolimod in Omani MS patients are similar to those determined by standard clinical trials and real-world retrospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, College of Medicine & Health Sciences, Sultan Qaboos University and Sultan Qaboos University Hospital, University Medical City.
- Department of Statistics, College of Science, Sultan Qaboos University, Muscat, Oman.
- Pharmacology & Clinical Pharmacy Department, College of Medicine & Health Sciences, Sultan Qaboos University, Muscat, Oman.
- Pharmacy Department, Sultan Qaboos University Hospital, University Medical City, Muscat, Oman.
Zitieren
APA
Al-Hashmi, G. K. H., Al-Asmi, A., Islam, M. M., Al-Zakwani, I., Butt, M., Al-Qassabi, A., Al-Abri, H., & Gujjar, A. R. (2025). Effectiveness and Safety Profile of Fingolimod in Treating Omani Patients with Multiple Sclerosis: A single tertiary centre experience. Sultan Qaboos University Medical Journal, 25(1), 225-232. https://doi.org/10.18295/2075-0528.2829
Vancouver
Al-Hashmi GKH, Al-Asmi A, Islam MM, Al-Zakwani I, Butt M, Al-Qassabi A, et al. Effectiveness and Safety Profile of Fingolimod in Treating Omani Patients with Multiple Sclerosis: A single tertiary centre experience. Sultan Qaboos University Medical Journal. 2025;25(1):225-232. doi:10.18295/2075-0528.2829
BibTeX
@article{AlHashmi2025,
author = {Al-Hashmi, Ghaida K H and Al-Asmi, Abdullah and Islam, M Mazharul and Al-Zakwani, Ibrahim and Butt, Mehwish and Al-Qassabi, Ahmed and Al-Abri, Haifa and Gujjar, Arunodaya R},
title = {Effectiveness and Safety Profile of Fingolimod in Treating Omani Patients with Multiple Sclerosis: A single tertiary centre experience},
journal = {Sultan Qaboos University Medical Journal},
year = {2025},
volume = {25},
number = {1},
pages = {225--232},
doi = {10.18295/2075-0528.2829}
}
EUVIMED